GlassScriptPhysician profile
Michelle Ruddock
NPI 1508411158
$992.49
in general payments reported to CMS, 2019-2025
14 companies · $36.37 in 2025
The $36.37 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $34.82 · 2023: $249 · 2024: $672 · 2025: $36.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $166.34 | 2024 | Impella |
| Exact Sciences Corporation | $131.32 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $123.25 | 2023-2024 | |
| Amgen INC. | $106.62 | 2024-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $86.23 | 2023-2024 | |
| Glaxosmithkline, LLC. | $76.00 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $68.95 | 2022-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $64.46 | 2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $57.70 | 2023-2024 | Airsupra, Breztri |
| Lundbeck LLC | $34.86 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $23.59 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $21.83 | 2024 | Eliquis |
| Verona Pharma, INC. | $16.86 | 2025 | Ohtuvayre |
| Dexcom, INC. | $14.48 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Ruddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.